CN1236632A - Medicinal composition for treating recurrent aphthae - Google Patents
Medicinal composition for treating recurrent aphthae Download PDFInfo
- Publication number
- CN1236632A CN1236632A CN 98113221 CN98113221A CN1236632A CN 1236632 A CN1236632 A CN 1236632A CN 98113221 CN98113221 CN 98113221 CN 98113221 A CN98113221 A CN 98113221A CN 1236632 A CN1236632 A CN 1236632A
- Authority
- CN
- China
- Prior art keywords
- zinc
- pharmaceutical composition
- preparation
- salviae miltiorrhizae
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A medicinal composition for treating recurrent aphthae is prepared from polyglycoside of common threewingnut root, extract of red sage root, zinc preparation and iron preparation, and features conenient application, high curative effect and low by-effect. Said medicinal composition can be used as matrix to add it to other carriers such as toothpaste or medicinal membrane.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of oral ulcer, particularly a kind of pharmaceutical composition for the treatment of recurrent aphtha.
Recurrent aphtha is the oral ulcer disease of complicated cyclic recurrence of a kind of common and cause of disease.In recent years research thinks that this disease is main and body's immunological function is unbalance, and the end is circulatory disturbance a little, and serum microelement changes substantial connection.Still lack specific medicament on the clinical treatment at present, the equal ubiquity curative effect of used various Therapeutic Method and preparation is undesirable, and the expense height fails to solve the recurrence problem.
The pharmaceutical composition that the purpose of this invention is to provide a kind of eutherapeutic treatment recurrent aphtha.
Pharmaceutical composition of the present invention is made up of Tripterygium glycosides, Radix Salviae Miltiorrhizae extractum, zinc preparation, iron preparation.Zinc preparation wherein is zinc gluconate or zinc sulfate, and iron preparation is ferrous sulfate or ferrous succinate.
Each constituent content following (weight percent meter, as follows): Tripterygium glycosides 0.2-0.9; Radix Salviae Miltiorrhizae extractum 86.7-94.8; Zinc preparation 0.2-0.9; Iron preparation 4.7-12.0.
Preferred each constituent content is: Tripterygium glycosides 0.8; Radix Salviae Miltiorrhizae extractum 93.7; Zinc preparation 0.8; Iron preparation 4.7.
Can also add a small amount of Borneolum Syntheticum in this pharmaceutical composition.
Studies confirm that the outbreak of recurrent aphtha and serum zinc, iron content are relevant, add with zinc, iron preparation treatment and can improve curative effect.Through clinical observation, using the remarkable effective percentage of this medicine composite for curing recurrent aphtha is 92.23%, is 71.43% and organize remarkable effective percentage with the treatment of Radix Tripterygii Wilfordii, Radix Salviae Miltiorrhizae, and only organizing remarkable effective percentage with the treatment of zinc, iron preparation is 28.92%, through contrast, significant difference (P＜0.01) is arranged.Studies show that by what the adjusting to immune function in recurrent aphthous ulcers influenced pharmaceutical composition of the present invention can significantly improve CD3, CD4, the CD4/CD8 ratio among the t lymphocyte subset group, reduce IgG ratio (P＜0.01).Curative effect and matched group only relatively have significant difference (P＜0.01) with the matched group of Radix Salviae Miltiorrhizae, zinc, iron preparation.Tip circulating immune complex and oxygen-derived free radicals effect be studies have shown that, after the treatment, can significantly reduce PEG-CIC ratio (P＜0.01), reduce SOD ratio, rising MDA ratio (P＜0.01).The trace element change studies show that zinc, iron content are improved in the patients serum of medicine composite for curing of the present invention, and contrast has significant difference (P＜0.01) before and after the treatment.Reach a conclusion according to above result of study, this medicine composite for curing recurrent aphtha mechanism is by regulating body's immunological function, microcirculation improvement, the oxygen metabolism of free radical everywhere in the promotion body, improve the serum microelement contents level, thereby disease is eased.
Pharmaceutical composition of the present invention adds in other carriers as substrate, and as toothpaste, medicine film etc., substrate generally accounts for the 30-45% of gross weight.In addition, the main component of pharmaceutical composition is a Chinese herbal medicine, and side effect is little, and convenient the use is a kind of pharmaceutical composition of eutherapeutic treatment recurrent aphtha.
Embodiment one:
Each constituent content is as follows: Tripterygium glycosides 0.8; Radix Salviae Miltiorrhizae extractum 93.7; Zinc gluconate 0.8; Ferrous sulfate 4.7.Embodiment two:
Each constituent content is as follows: Tripterygium glycosides 0.7; Radix Salviae Miltiorrhizae extractum 93.6; Zinc gluconate 0.9; Ferrous sulfate 4.8.Embodiment three:
Each constituent content is as follows: Tripterygium glycosides 0.6; Radix Salviae Miltiorrhizae extractum 93.7; Zinc gluconate 0.7; Ferrous sulfate 5.0.Embodiment four:
Each constituent content is as follows: Tripterygium glycosides 0.5; Radix Salviae Miltiorrhizae extractum 94.0; Zinc sulfate 0.6; Ferrous succinate 4.9.Embodiment five:
Each constituent content is as follows: Tripterygium glycosides 0.2; Radix Salviae Miltiorrhizae extractum 87.8; Zinc sulfate 0.5; Ferrous succinate 11.5.Embodiment six:
Each constituent content is as follows: Tripterygium glycosides 0.3; Radix Salviae Miltiorrhizae extractum 90.0; Zinc sulfate 0.4; Ferrous succinate 9.3.Embodiment seven:
Each constituent content is as follows: Tripterygium glycosides 0.9; Radix Salviae Miltiorrhizae extractum 92.5; Zinc sulfate 0.3; Ferrous sulfate 6.3.Embodiment eight:
Each constituent content is as follows: Tripterygium glycosides 0.9; Radix Salviae Miltiorrhizae extractum 92.0; Zinc gluconate 0.2; Ferrous succinate 6.9.
Claims (6)
1, a kind of pharmaceutical composition for the treatment of recurrent aphtha is characterized in that being made up of Tripterygium glycosides, Radix Salviae Miltiorrhizae extractum, zinc preparation, iron preparation.
2, pharmaceutical composition according to claim 1 is characterized in that each constituent content following (weight percent meter, as follows): Tripterygium glycosides 0.2-0.9; Radix Salviae Miltiorrhizae extractum 86.7-94.8; Zinc preparation 0.2-0.9; Iron preparation 4.7-12.0.
3, pharmaceutical composition according to claim 1 is characterized in that preferred each constituent content is: Tripterygium glycosides 0.8; Radix Salviae Miltiorrhizae extractum 93.7; Zinc preparation 0.8; Iron preparation 4.7.
4, pharmaceutical composition according to claim 1 is characterized in that described zinc preparation is zinc gluconate or zinc sulfate.
5, pharmaceutical composition according to claim 1 is characterized in that described iron preparation is ferrous sulfate or ferrous succinate.
6, pharmaceutical composition according to claim 1 is characterized in that can also adding a small amount of Borneolum Syntheticum in the pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98113221A CN1067580C (en) | 1998-05-22 | 1998-05-22 | Medicinal composition for treating recurrent aphthae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98113221A CN1067580C (en) | 1998-05-22 | 1998-05-22 | Medicinal composition for treating recurrent aphthae |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1236632A true CN1236632A (en) | 1999-12-01 |
| CN1067580C CN1067580C (en) | 2001-06-27 |
Family
ID=5222979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98113221A Expired - Fee Related CN1067580C (en) | 1998-05-22 | 1998-05-22 | Medicinal composition for treating recurrent aphthae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1067580C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2396009A1 (en) * | 2009-02-12 | 2011-12-21 | Monica Bonucci | Compositions for the treatment of aphthous stomatitis |
| CN102727579A (en) * | 2011-04-11 | 2012-10-17 | 苏州瑞美科生物技术有限公司 | Pharmaceutical composition for treatment of oral ulcers |
-
1998
- 1998-05-22 CN CN98113221A patent/CN1067580C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2396009A1 (en) * | 2009-02-12 | 2011-12-21 | Monica Bonucci | Compositions for the treatment of aphthous stomatitis |
| CN102727579A (en) * | 2011-04-11 | 2012-10-17 | 苏州瑞美科生物技术有限公司 | Pharmaceutical composition for treatment of oral ulcers |
| CN102727579B (en) * | 2011-04-11 | 2015-11-18 | 苏州瑞美科生物技术有限公司 | A kind of pharmaceutical composition being used for the treatment of oral ulcer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1067580C (en) | 2001-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1062144C (en) | Yisuishengxue chinese medicine preparation for tonifying marrow and promoting generation of blood | |
| CN1057451C (en) | Children coryza medicine and preparing method | |
| CN102145128B (en) | Medicinal composition for preventing and treating cardiac and cerebral vascular diseases and preparation method thereof | |
| CN1085785A (en) | Ginseng deer YIYUAN GAO and preparation method thereof | |
| Yamaguchi | Immunomodulation by medicinal plants | |
| CN1067580C (en) | Medicinal composition for treating recurrent aphthae | |
| CN1055638C (en) | Selenium-riched Chinese caterpillar fungus oral liquor and its prepn. method | |
| CN1103228C (en) | Fresh deer's blood health-care medicated wine and its preparation method | |
| Cheney | Aloe drug in human therapy | |
| Srikantia et al. | Human requirements of ascorbic acid | |
| CN101953869B (en) | Medicinal composition for resisting myocardial ischemia and hypoxia | |
| CN1085082C (en) | Recipe of Fumailing for curing arrhythmic coronary heart disease and producing method | |
| CN1063655C (en) | Pure traditional Chinese medicine concentrated capsule for treating hepatitis B | |
| CN102205016B (en) | Medicament for treating phlegm and blood stasis coronary heart disease caused by atherosclerosis | |
| CN1048635C (en) | Squame curing liquid | |
| GB2393906A (en) | Psoriasis treatment | |
| CN1176683C (en) | Medicine for treating hepatitis B and other hepatosis | |
| CN1092304A (en) | Shufeining (medicine for lung disease) pill | |
| CN1196263A (en) | Chinese medicinal preparation for treating leukemia | |
| CN1157206C (en) | Asthma-treating medicine liquid | |
| CN1176673C (en) | Compound and powder prescription | |
| CN1289129C (en) | Chinese herbal medicine for treating hepatitis | |
| CN110368342A (en) | It is a kind of with nti-freckle, anti-wrinkle, whitening and softening skin effect shin moisturizer | |
| CN1463736A (en) | A pharmaceutical compound for treating coronary disease and stenocardia | |
| CN1251764A (en) | Exterior-applied ointment for treating rheumatic arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |